Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Cancer - 1 Jun 2026

Passiglia Francesco, Passaro Antonio, Gariazzo Eleonora, Montrone Michele, Pasello Giulia, Tiseo Marcello, Russano Marco, Citarella Fabrizio, Muscarella Lucia Anna, Pozzessere Daniele, Bria Emilio, Roca Elisa, Cerea Giulio, Russo Alessandro, Grisanti Salvatore, Bulotta Alessandra, Veccia Antonello, Biello Federica, Lo Russo Giuseppe, Pilotto Sara, Genova Carlo, Cortinovis Diego, Minuti Gabriele, Meoni Giulia, Gori Stefania, Reale Maria Lucia, Pavan Alberto, Ramundo Matteo, Grossi Francesco, Parra Hector Soto, Scotti Vieri, Vavalà Tiziana, Sini Claudio, Sergi Concetta, Pelizzari Giacomo, Chiari Rita, Stanzione Brigida, Favaretto Adolfo, Leone Francesco, Bettini Anna Cecilia, Pagano Maria, Tondulli Luca, Toschi Luca, Lacidogna Gaetano, Bennati Chiara, Catanese Silvia, Malapelle Umberto, Giannarelli Diana, Novello Silvia

Abstract excerpt

BACKGROUND: The treatment landscape for metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) is rapidly evolving, with the development of specific targeted therapies. The bispecific antibody amivantamab is the new standard of care for this population but real-world safety and efficacy data are lacking. METHODS: This is a multicenter, retrospective, observational study conducted on...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Exons
Share to Italy
Share to Lung Neoplasms
Share to Mutagenesis, Insertional
Share to Registries

Source

Identifiers

PMID: 42216441
DOI: 10.1002/cncr.70476

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.PMID 42216441Read ↗

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabSemantic proximity Read ↗

A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.Semantic proximity Read ↗

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancerSemantic proximity Read ↗

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerSemantic proximity Read ↗

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.Semantic proximity Read ↗

The development of amivantamab for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.Semantic proximity Read ↗

Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced PractitionersSemantic proximity Read ↗

Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.